TruNiagen

Longevity2020: Day 4 recap

Latest articles

SuperAger brains work all the tangles

New research demonstrates that SuperAger brains can resist the protein tangles that lead to Alzheimer's. Northwestern Medicine scientists have showed that SuperAgers' brains have resistance...

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

SuperAger brains work all the tangles

New research demonstrates that SuperAger brains can resist the protein tangles that lead to Alzheimer's. Northwestern Medicine scientists have showed that SuperAgers' brains have resistance...

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...
ChromaDex Tru Niagen

Yesterday at Longevity2020 was all about how the Longevity sector is growing an investment category.

Speakers included top investors, as well as the entrepreneurs behind some of the most exciting companies in the field.

Things got going with Burnbrae Group’s Jim Mellon, who set the scene. Mellon, also the Chairman of Juvenescence, spoke about the impact of COVID-19 on the markets in these volatile times. He warned that “inflation is coming back with vengeance” over the next couple of years due to the huge amounts of liquidity being pumped into the economy by central banks and governments.

Longevity2020 longevity investing

Despite the obvious impact on the world economy, Mellon is optimistic about the state of the biotech and healthcare sector. “Everyone’s going to be more worried about health, and governments will be prepared to spend to avoid the next pandemic, which will come along if things don’t change – be it microbial or viral,” he said.

In terms of the direct impact on the Longevity sector, Mellon said that extending lifespan may not be top of the investment agenda for a while. However he went on to point out that technologies focused on improving the immune resilience of the elderly population will be a key focus, citing work ongoing to explore the potential benefit of rapamycin as an example.

Longevity Capital’s Kate Batz brought a Silicon Valley perspective, expressing some concern about the hype around the sector and that the complexities of the biology of aging will mean that many companies will not provide ROIs proportional to their valuations. She stressed the importance of funding the Longevity sectors that show greatest prospects for fast and economical real-world results.

AgeTech is a booming segment of the Longevity market, and Lorraine Morley of AgeTech Accelerator shared extensive data with the audience. Of particular interest was her assessment of where gaps in the market exist, and where future opportunities might lie. These ranged from virtual home diagnostics and robot assistants to mobility assistance and job retraining.

Juvenescence’s Greg Bailey guided the audience through the company’s latest developments, including its plans to raise  $100 – $150 million in new capital, as well as its planned product launch of a direct-to-consumer drink product that is geroprotective, neuroprotective and cardioprotective.

Dmitry Kaminskiy of Deep Knowledge Ventures expressed concerns about the lack of an efficient experimentation platform for the Longevity industry, and the limitations of mice as a model organism. He made the case that Longevity FinTech is the “best and most de-risked sector for the next several years“ and that AI for Longevity is a positive area as “all other companies across all sectors in the industry will need AI solutions.”

Fight Aging!’s Reason returned to the stage to encourage investors to consider the key question “Is it repair?” when evaluating Longevity companies. He points out that Longevity companies “must be able to point to a specific form of cell or tissue damage or loss that is aggressively reversed by their program.”

Longevity2020

The audience also heard from LyGenesis’ Michael Hufford, who spoke about his company’s work to commercialise regenerative medicine with its liver regeneration technology. LyGenesis is due to begin a Phase 2a clinical trial for patients with end stage liver disease this year.

The Buck Institute’s Simon Melov provided insight into Gerostate Alpha, his new company that received Seed funding from Y Combinator last year. The company targets aging via three complementary drug development pipelines: repurposing off-patent approved drugs, natural cannabinoid products, and novel small molecules.

Ronjon Nag from R42 Group shared some interesting insights into what early stage investors are looking for in potential investee companies. While having lots of customers and significant revenues are obvious plus points, a company with a team that has worked together for more than three years also scores very highly. For investors, Nag pointed out that a company in Phase 1 trials only has a 15% chance of commercialisation, so having a diversified portfolio is key.

Finally, Longevity Vision Fund’s Sergey Young shared some lessons to be learned from COVID-19 that may help guide investors towards potentially successful investments. Among several points, Young picks out AI technologies that enable early prediction of an outbreak, as well as companies developing mass diagnostics and testing capabilities.

In our final session today, it’s all about what you can do to address your Longevity now. Hear about drugs, supplements and lifestyle changes that you can make today to beat aging.

Longevity Start Now

Image credit: ZoFot / Shutterstock
Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
ChromaDex Tru Niagen

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Apollo Neuro

Related articles

Leading NAD+ company ChromaDex announces $25m raise

LA-based company ChromaDex announces that it has entered into a securities purchase agreement for the sale of $25m of its common stock in a...

NIA announces funding for longevity clinical trials

New funding opportunity for longevity clinical trials from National Institute on Aging emphasises preventing aging and age-related disease. The NIA, which is part of the...

Andreessen Horowitz leads $7m seed funding: Bold

Digital health and wellness company bags $7 million in seed funding led by Andreessen Horowitz. Bold focuses on disease prevention and healthy aging. Using personalised and...

Charles River to acquire Cognate BioServices for $875m

Charles River Laboratories signs $875 million cash deal to acquire cell and gene manufacturer Cognate BioServices. Charles River has announced plans to acquire Cognate BioServices,...

$1.1B biotech SPAC good news for longevity

Bioengineered human tissue company Humacyte nears biotech SPAC deal to go public. Humacyte, a transformative biotech platform company capable of manufacturing universally-implantable bioengineered human tissue...
TruNigen pf